Valby, Denmark, 2014-02-28 17:01 CET (GLOBE NEWSWIRE) -- In accordance with Section 6 of the Danish Statutory Order on Issuers’ Disclosure Obligations, H. Lundbeck A/S is required to publish the total number of voting rights and the size of the share capital in H. Lundbeck A/S as per the end of a month where changes therein have occurred.
Referring to Corporate Release no 524 dated 19 February 2014, please find below a statement regarding the total number of voting rights and share capital in H. Lundbeck A/S as per 28 February 2014.
Number of shares
(nominal value DKK 5)
|Number of votes|
|Palle Holm Olesen||Mads Kronborg|
|Chief Specialist, Investor Relations||Media Relations Manager|
|+45 36 43 24 26||+45 36 43 30 00|
|Specialist, Investor Relations|
|+45 36 43 33 86|
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our development and distribution of pioneering treatments continues to make a difference to people living with brain diseases. Our key areas of focus are alcohol dependence, Alzheimer’s disease, depression/anxiety, epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia and stroke.
Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales, and are committed to improving the quality of life of people living with brain diseases. Our pipeline consists of several late-stage development programs and our products are available in more 100 countries. We have research centers in China, Denmark and the United States, and production facilities in China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of DKK 15.3 billion in 2013 (EUR 2.0 billion; USD 2.7 billion).